Protalix BioTherapeutics, Inc. PLX NYSE

NYSE • Healthcare • Biotechnology • US • USD

SharesGrow Score

53/100

2/7 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Protalix BioTherapeutics, Inc. (PLX) generated $2.03M in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $1.24M, free cash flow was $3.27M.

Free cash flow margin was 35.8% of revenue. Cash conversion ratio was 1.85x, indicating earnings are backed by cash.

Criteria supported by this page:

HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
MOAT (28/100, Fail) — limited free cash flow weakens the competitive position
INCOME (10/100) — Cash conversion ratio was 1.85x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 53/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score

53/100

SG Score

View full scorecard →

✓

VALUE

100/100

Price-to-Earnings & upside

→ Valuation

✓

FUTURE

75/100

Analyst consensus

→ Forecast

PAST

50/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

28/100

Proven by this page

GROWTH

40/100

→ Income

✗

INCOME

10/100

→ Income

Protalix BioTherapeutics, Inc. Cash Flow History

Metric	TTM	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025
Operating Cash Flow	$-11.99M	$2.03M	$-3.73M	$-5.23M	$-5.06M
Capital Expenditure	$0.00	$1.24M	$-498K	$-431K	$-306K
Free Cash Flow	$-11.99M	$3.27M	$-4.23M	$-5.66M	$-5.36M